Novo Nordisk Drug Pipeline

Goals

To find information on the diseases treated and drug advancements for each of the target drugs. The drugs to be researched will include phase 3 drugs i.e. semaglutide, concizumab, & somapacitan  and filed drugs i.e. oral semaglutide.

Early Findings

Phase 3 Drugs

Semaglutide Obesity 

  • Semaglutide is a once per week injection that was approved in 2017 for the treatment of type 2 diabetes.
  • The results of a phase 2 trial reported that the drug helped 65% of adults loose at least 10% of their body weight over 52 weeks.

Concizumab 

Somapacitan 

Filled Drugs

Oral Semaglutide 

Proposed next steps:

You need to be the project owner to select a next step.